Document is current

Article History

Received: 1 August 2024

Accepted: 21 January 2025

First Online: 21 February 2025

Competing interests

: M.J.E, P.E., J.F.A., S.M., E.G.A., A.D., Z.V., N.M., E.S., C.Y., and H.K.B. report no competing interests. E.A. reports receiving honoraria from Sandoz and Seagen and consulting fees from AstraZeneca and Novartis. M.B.N. reports speaker honoraria and consulting fees from Novartis and Exact Sciences, outside the scope of this submitted work. N.C., R.V., and C.P. were employees of NeoGenomics at the time of data generation and manuscript preparation. P.L.B. reports research funding (to the institution) from Amgen, AstraZeneca, Bayer, Bicara, Bristol Myers Squibb, Genentech/Roche, Gilead, GlaxoSmithKline, Lilly/Loxo, Medicenna, Merck, Nektar, Novartis, PTC Therapeutics, Sanofi, SeaGen, Servier, SignalChem Life Sciences, Takeda, and Zymeworks. He also reports uncompensated honoraria/consultancy with Zymeworks, Lilly, Seattle Genetics, Merck, Amgen, Gilead, Janssen, and Repare. L.L.S. serves on scientific advisory boards for Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea, and Break Through Cancer. She also reports clinical trial support (to the institution) from Novartis, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Mirati, BioNTech, 23andMe, and EMD Serono. Additionally, her spouse holds stock ownership in Agios and has leadership roles at Treadwell Therapeutics. D.W.C. reports consultancy and advisory relationships with AstraZeneca, Daiichi Sankyo, GenomeRx, Gilead, GlaxoSmithKline, NeoGenomics, Lilly, Merck, Novartis, Pfizer, Roche and SAGA; research funding (to the institution) from AstraZeneca, Guardant Health, Grail, Gilead, GlaxoSmithKline, NeoGenomics, Knight, Merck, Pfizer, ProteinQure, and Roche.